

Open Peer Review on Qeios

Anti-CD19-DM4 Immunoconjugate SAR3419

National Cancer Institute

Source

National Cancer Institute. <u>Anti-CD19-DM4 Immunoconjugate SAR3419</u>. NCI Thesaurus. Code C71009.

An immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Anti-CD19-DM4 conjugate SAR3419 targets the cell surface antigen CD19, found on a number of B-cell-derived cancers. Upon antibody/antigen binding and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CD19-expressing tumor cells.

Qeios ID: 41GX2V · https://doi.org/10.32388/41GX2V